Site Editor

William J. Gradishar, MD, FACP, FASCO


Anita Mamtani, MD, on When Can Axillary Dissection Be Avoided in Patients With Breast Cancer?

Posted: Friday, May 12, 2023

Anita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses the clinical implications of study findings on whether axillary lymph node dissection is required for patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. Neoadjuvant chemotherapy did not appear to reduce the risk of lymph node dissection in this cohort, although upfront surgery allowed for de-escalated chemotherapy regimens.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.